Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Public ClinicalTrials.gov record NCT00322556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)
Study identification
- NCT ID
- NCT00322556
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- CSL Behring
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Interventions
- Immunoglobulins Intravenous (Human) Drug
Drug
Eligibility (public fields only)
- Age range
- 4 Years to 71 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Oct 25, 2012
2005 – 2008
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Contact CSL Behring for facility details | Los Angeles | California | 90027 | — |
| Contact CSL Behring for facility details | Centennial | Colorado | 80112 | — |
| Contact CSL Behring for facility details | North Palm Beach | Florida | 33408 | — |
| Contact CSL Behring for facility details | St. Petersburg | Florida | 33701 | — |
| Contact CSL Behring for facility details | Fort Wayne | Indiana | 46815 | — |
| Contact CSL Behring for facility details | Indianapolis | Indiana | 46202 | — |
| Contact CSL Behring for facility details | Iowa City | Iowa | 52242 | — |
| Contact CSL Behring for facility details | Rochester | Minnesota | 55905 | — |
| Contact CSL Behring for facility details | St Louis | Missouri | 63104-1095 | — |
| Contact CSL Behring for facility details | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00322556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2012 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00322556 live on ClinicalTrials.gov.